The Indian government launched a new national platform to boost biomedical research and drug development domestically, reducing reliance on imported pharmaceutical active ingredients.
The initiative connects academic institutions, startups and manufacturers with shared infrastructure for discovery, preclinical testing and scale-up. Officials said domestic API production strengthens supply chain resilience after pandemic-era shortages.
Policy incentives include funding pools and streamlined regulatory pathways for innovative therapies developed within the platform. India remains a major generic drug exporter seeking higher-value research capabilities.
Industry leaders welcomed collaboration opportunities but asked for clarity on intellectual property and pricing controls. Public health advocates hope the platform accelerates treatments for diseases prevalent in India.
Implementation timelines span multiple years, with pilot hubs planned in pharmaceutical clusters. International partners may participate under technology transfer agreements subject to national security review.
India launched a national biomedical innovation platform to accelerate domestic drug discovery and reduce imported active pharmaceutical ingredient reliance. Academic and industry hubs will share infrastructure under multi-year implementation plans.
Startup incubators linked to the platform will prioritize vaccines and chronic disease therapies with high domestic demand. Regulatory agencies promised fast-track reviews for innovations meeting national priority lists.
Industry ministers said the platform will coordinate with existing pharmaceutical manufacturing incentive schemes.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources: